These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32713096)

  • 21. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
    Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
    Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
    Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
    Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
    Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and clinical significance of mammalian target of rapamycin phosphorylation (p-mTOR) and vascular endothelial growth factor (VEGF) in clear cell carcinoma of the ovary.
    Khemapech N; Pitchaiprasert S; Triratanachat S
    Asian Pac J Cancer Prev; 2012; 13(12):6357-62. PubMed ID: 23464458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
    Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
    Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.
    Rogers-Broadway KR; Chudasama D; Pados G; Tsolakidis D; Goumenou A; Hall M; Karteris E
    Int J Oncol; 2016 Jul; 49(1):133-43. PubMed ID: 27211906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomic investigating the cooperative lethal effect of EGFR and MDM2 inhibitors on ovarian carcinoma.
    Chang SJ; Liao EC; Yeo HY; Kuo WH; Chen HY; Tsai YT; Wei YS; Chen YJ; Wang YS; Li JM; Shih CC; Chan CH; Lai ZY; Chou HC; Chuang YJ; Chan HL
    Arch Biochem Biophys; 2018 Jun; 647():10-32. PubMed ID: 29655550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
    Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
    Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
    Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
    Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.